BioSpace News Archive

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA®, Merck’s anti-PD-1 therapy, has been approved by the China National Drug Administration (CNDA) for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

Company Commercializes Accula™ System in EU and U.S.and Prepares for Expansion

Same store sales decreased 0.4%; excluding impact of loyalty points redeemed, same store sales increased 1.3%

The Medicines Company will host a conference call and audio webcast on Wednesday, August 1, 2018, at 8:30 a.m. EDT

Acceleron Pharma Inc. announced it will host a webcast and conference call on Thursday, August 2, 2018 at 5:00 p.m. EDT

Organizations from emerging biopharma to the largest pharmaceutical companies are improving field productivity and driving better customer engagement

Increases Second Quarter Revenues 11% to $5.7 Billion

Foresee Pharmaceuticals Co., Ltd. announced that it has successfully completed a Phase 1 multiple ascending dose (MAD) clinical study with FP-045

Second-quarter revenue of $2.8 billion increased 9 percent on a reported basis and 4 percent on an operational basis

With Voluntary Dismissal of Infringement Suit Against Sandoz, Omeros Wraps Up All Pending ANDA Litigation